A facile, green, one-pot oxidation of primary alcohols to carboxylic acids with broad substrate applicability has been developed by employing an expedient catalytic system consisting of 1-Me-AZADO+X-/NaClO2.

Choline is an essential nutrient for all living cells and is produced extracellularly by sequential degradation of phosphatidylcholine (PC). However, little is known about how choline is produced extracellularly. Here, we report that ENPP6, a choline-specific phosphodiesterase, hydrolyzes glycerophosphocholine (GPC), a degradation product of PC, as a physiological substrate and participates in choline metabolism. ENPP6 is highly expressed in liver sinusoidal endothelial cells and developing oligodendrocytes, which actively incorporate choline and synthesize PC. ENPP6-deficient mice exhibited fatty liver and hypomyelination, well known choline-deficient phenotypes. The choline moiety of GPC was incorporated into PC in an ENPP6-dependent manner both in vivo and in vitro. The crystal structure of ENPP6 in complex with phosphocholine revealed that the choline moiety of the phosphocholine is recognized by a choline-binding pocket formed by conserved aromatic and acidic residues. The present study provides the molecular basis for ENPP6-mediated choline metabolism at atomic, cellular and tissue levels.

The article contains sections titled: 1. Introduction 2. Properties 2.1. Physical Properties 2.2. Chemical Properties 3. Production 3.1. Acrolein by Propene Oxidation 3.2. Methacrolein 4. Quality and Analysis 5. Handling, Storage, and Transportation 6. Uses and Production Data 7. Toxicology and Ecotoxicology 7.1. Toxicology 7.2. Ecotoxicology Acrolein is the simplest unsaturated aldehyde. It is an important intermediate in the production processes of a variety of substances. The main use of isolated acrolein is in the production of d,l ‐methionin, but in far more production processes, acrolein is used without purification. Acrolein is an extremely reactive chemical and, in very low concentrations, acts as a very effective broad‐spectrum biocide. Methacrolein is produced commercially as an organic intermediate, which is used as building block for chain expansions or, in limited application, in the synthesis of flavors and fragrances.

No abstract

The effects of propranolol (PRO), a nonselective ␤-adrenergic receptor (␤-AR) antagonist with membrane-stabilizing action on bone metabolism, were examined in spontaneously hypertensive rats (SHR) showing osteoporosis with hyperactivity of the sympathetic nervous system. Treatment of SHR with PRO at 1 and 5 mg/kg p.o. for 12 weeks increased bone mass of the lumbar vertebra and proximal tibia without affecting blood pressure, but PRO at 50 and 100 mg/kg with hypotensive action did not increase bone mass. Next, the effects of PRO at 0.1, 1, and 10 mg/kg on bone status were examined in more detail. Compared with the SHR control, not only bone mass but also biomechanical parameters of strength and toughness of the lumbar vertebrae were increased in SHR treated with PRO at 0.1 and 1 mg/kg, suggesting antiosteoporotic action. PRO at 1 mg/kg statistically increased histomorphometry indices of bone formation, whereas PRO at doses of 0.1, 1, and 10 mg/kg decreased those of bone resorption. Antiosteoporotic effect of PRO is attenuated at 10 mg/kg compared with 0.1 and 1 mg/kg. In addition, treatment with timolol, a nonselective ␤-AR antagonist without membrane-stabilizing action, or butoxamine, a selective ␤2-AR antagonist, at 1 mg/kg increased bone mass in SHR. These results suggested that treatment of SHR with ␤-blockers at low dose improved bone loss and bone fragility. This antiosteoporotic effect of ␤-blockers seems to be caused by the blocking action of ␤2-AR, regardless of the membrane-stabilizing action.